In patients with resected stage III mismatch repair-deficient colon cancer, adjuvant atezolizumab plus standard chemotherapy ...
FG-M108 plus nab-paclitaxel and gemcitabine (AG) as first-line (1L) treatment for patients with Claudin-18.2 (CLDN18.2) positive locally advanced unresectable or metastatic pancreatic cancer (PC): ...
Targeted Next-Generation Sequencing of Cell-Free DNA to Detect MYC-Immunoglobulin Translocation and Epstein-Barr Virus DNA in Plasma of Burkitt Lymphoma Patients in East Africa The following ...
Researchers have uncovered the mechanisms behind three unique subtypes of mismatch repair deficient high-grade gliomas. The findings provide a clearer understanding of how these tumors develop, ...
Patients with mismatch repair deficient gastric cancer demonstrated better median overall survival when skipping perioperative chemotherapy, according to a preprint study. Median overall survival is ...
The initial idea behind the study came from patients with rectal cancer, and we saw that a proportion of patients with mismatch repair deficient (MMRd) tumors did not do well with standard therapy ...
The Dako Omnis test identifies mismatch repair deficient colorectal cancer patients eligible for Opdivo or Opdivo plus Yervoy treatment. Mismatch repair deficiency results in DNA replication errors, ...
When Vanessa was diagnosed with advanced colon cancer in 2014, just before her 60th birthday, the mother and grandmother learned the cancer had already spread to her stomach and liver. Even after a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results